Canada approves GSK’s Arexvy vaccine for RSV protection in adults 50-59 at elevated risk

Canada approves GSK’s Arexvy vaccine for RSV protection in adults 50-59 at elevated risk

In a crucial development for public health, Health Canada has extended its approval for GlaxoSmithKline’s Arexvy vaccine to include adults aged 50 to 59 who face a heightened risk from respiratory syncytial virus (RSV) due to underlying health conditions. This expanded approval marks a significant move in Canada’s battle against RSV, a respiratory virus that, […]

EC approves Pfizer’s ABRYSVO RSV vaccine for infants and older adults

EC approves Pfizer’s ABRYSVO RSV vaccine for infants and older adults

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for ABRYSVO, its bivalent respiratory syncytial virus (RSV) prefusion F vaccine. This groundbreaking vaccine aims to protect infants through maternal immunization and individuals 60 years and older against lower respiratory tract disease (LRTD) caused by RSV. ABRYSVO Offers Dual Protection Against Severe RSV […]

FDA greenlights Pfizer’s ABRYSVO vaccine for shielding infants from RSV

FDA greenlights Pfizer’s ABRYSVO vaccine for shielding infants from RSV

The US Food and Drug Administration (FDA) has granted approval to Pfizer Inc.’s ABRYSVO, a bivalent Respiratory Syncytial Virus prefusion F (RSVpreF) vaccine. This cutting-edge vaccine is designed for the prevention of Lower Respiratory Tract Disease (LRTD) and severe LRTD caused by RSV in infants. Notably, the vaccine works through active immunization of pregnant individuals […]

Pfizer RSVpreF vaccine candidate gets another FDA breakthrough therapy status

Pfizer RSVpreF vaccine candidate gets another FDA breakthrough therapy status

Pfizer said that PF-06928316 (RSVpreF), its respiratory syncytial virus (RSV) vaccine candidate, has been granted breakthrough therapy designation from the US Food and Drug Administration (FDA). The breakthrough therapy designation is for the use of the vaccine candidate in the prevention of lower respiratory tract disease caused by RSV in patients aged 60 years or […]

Pfizer gets FDA breakthrough status for RSVpreF RSV vaccine candidate

Pfizer gets FDA breakthrough status for RSVpreF RSV vaccine candidate

Pfizer has secured breakthrough therapy designation for its respiratory syncytial virus (RSV) vaccine candidate — PF-06928316 (RSVpreF) from the US Food and Drug Administration (FDA) for the prevention of RSV-associated lower respiratory tract illness in infants from the time of birth up to six months by active immunization of pregnant women. According to Pfizer, the […]

Thermo Fisher to acquire molecular diagnostic company Mesa Biotech for up to $500m

Thermo Fisher to acquire molecular diagnostic company Mesa Biotech for up to $500m

Thermo Fisher Scientific has agreed to acquire California-based point-of-care molecular diagnostic company Mesa Biotech in a deal worth up to $500 million. The consideration includes nearly $450 million in cash and an additional amount of up to $100 million, which will be subject to Mesa Biotech achieving certain milestones post-acquisition. The molecular diagnostic company has […]

Pfizer begins phase 3 clinical trials of 20vPnC, RSVpreF, and MenABCWY vaccine candidates

Pfizer begins phase 3 clinical trials of 20vPnC, RSVpreF, and MenABCWY vaccine candidates

US pharma giant Pfizer has initiated four phase 3 clinical trials within its present pipeline of investigational vaccines. The company’s 20vPnC, which is a 20-valent pneumococcal polysaccharide conjugate vaccine candidate, will be evaluated in two phase 3 trials NCT04382326 and NCT04379713. Both the late-stage trials will evaluate a four-dose series in infants starting at the […]